Group Product Director - Professional Promotion, Gastroenterology
About the job
- A B.A. or B.S. is required.
- A minimum of 10 years of commercial or related business experience, including at least 5 years of successful pharmaceutical marketing, is required.
- People leadership experience is required.
- A demonstrated track record of business results, storytelling competencies, and comfort trying new things is required.
- The ability to influence large and diverse teams without direct authority is required.
- Strong verbal, written, executive communication, and presentation skills are required.
- Agency and vendor relationship management experience is required.
- A strong sense of urgency and big-picture orientation with attention to detail is required.
- Continual assessment of the competitive landscape to inform strategic choices is required.
- Innovation, proactivity, analytical strength, and overall business acumen are required.
- Leadership, decision-making, collaboration, and the ability to influence and work with a team to deliver results are required.
- Develop, retain, and motivate a high-performance marketing team in a fast-paced environment.
- Lead strategy and execution of HCP marketing strategies, positioning, messaging, and tactics to drive Gastroenterology performance across field-team personal promotion assets, including the Interactive Visual Aid, and non-personal promotion assets, including websites and HCP media plans.
- Partner with the Thought Leader Liaison team to manage Key Opinion Leader relationships and lead professional education strategy and execution through peer-to-peer programming and advisory boards.
- Partner with sales leadership and Learning Excellence teams to plan and execute regular field trainings that prepare field teams to communicate strategy and new data.
- Work with the Commercial Excellence team to translate data into meaningful insights that shape strategy.
- Partner with Medical Affairs, Global Marketing, Finance, Sales, and cross-franchise marketing to identify differentiation opportunities and develop plans and tactics for the U.S. business, including translating clinical data into commercial opportunities.
- Build relationships and work effectively with external agencies and internal partners to ensure prioritized tactical execution.
- Partner with legal, medical, regulatory, and HCC teams to obtain approval of marketing materials.
- Lead strategic and operational planning for cross-functional plans related to Gastroenterology data, competitor activities, and market events; deliver and continuously optimize the HCP Marketing Tactical plan.
- Develop employees on the team by supporting Human Resources Planning programs, including management development and training, to meet current and future business needs.
- Provide an environment that supports equal employment opportunity and values a diverse workforce.
- Meet key strategic brand imperatives and contribute to U.S. revenue performance and share goals.
- An MBA or other related advanced degree is preferred.
- Strong learning agility and command of clinical data are preferred.
- Sales or sales leadership experience is preferred.
- Demonstrated success partnering with sales teams is preferred.
- Commitment to learning emerging technologies such as AI through exploration, iteration, and applying new tools over time is preferred.
- Experience building team AI literacy and confidence, reinforcing trusted and responsible AI use, and applying AI-enabled insights with sound judgment is preferred.
About the company
Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
New Brunswick, New Jersey
Founded
1886
Get referred to Johnson & Johnson
See people who can refer or advise you
Simplify's Take
What believers are saying
- Second-quarter 2026 sales rose 6.6% to $25.3 billion, with raised full-year guidance.
- TREMFYA posted $2 billion quarterly sales in July 2026, growing 72.5%.
- CAPLYTA met its bipolar mania primary endpoint on September 21, 2026.
What critics are saying
- Talc litigation still threatens cash flow after the $5.5 billion settlement announced July 2026.
- Apollo's orthopedics talks signal DePuy Synthes weakness and forced portfolio shrinkage.
- AbbVie's etentamig and biosimilars pressure CARVYKTI, TREMFYA, and post-STELARA growth.
What makes Johnson & Johnson unique
- J&J has 28 billion-dollar products, reducing dependence on any single franchise.
- TREMFYA and DARZALEX offset STELARA erosion, proving resilient portfolio management.
- CAPLYTA, CARVYKTI, and RYBREVANT deepen leadership across psychiatry, cell therapy, and oncology.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Remote Work Options
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -2%1 year growth
↓ -2%2 year growth
↓ -1%Johnson & Johnson stock has surged 57% over the past year, outpacing the S&P 500's 17% return. Trading at approximately $270 per share, the stock appears expensive at 28.3 times trailing earnings. However, those trailing figures include STELARA, which lost market share to biosimilar competition and reduced operational sales growth by 460 basis points in Q2 2026. Excluding STELARA, the company achieved double-digit growth. The forward outlook looks more attractive, with the stock trading at 24.1 times fiscal 2026 earnings and 20.9 times 2027 estimates. Johnson & Johnson's portfolio includes 28 products generating over $1 billion annually each, with trailing twelve-month revenue near $98 billion. Meanwhile, TREMFYA grew 71% in Q2 2026, becoming the fastest-growing advanced therapy in Crohn's disease and ulcerative colitis. Operating margins improved to 26.8% from a three-year average of 25.7%, supporting expectations for continued margin expansion.
Johnson & Johnson shares rose 1.3% in pre-market trading following reports that Apollo Global Management is in discussions to acquire its orthopedics business for approximately $20 billion. Bloomberg News reported the potential deal could be finalised within weeks, citing people familiar with the matter. The orthopedics division generated $9.3 billion in revenue in 2025. However, the business has faced thousands of lawsuits related to its hip replacement devices. No transaction has been confirmed. Investors responded positively to news of the reported discussions and the potential valuation of the orthopedics unit.
Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.
Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.
Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.